NCT07037758

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 380 (estimated)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.

Conditions

• Extensive Stage Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Tarlatamab	Administered as an IV infusion.
DRUG	AB248	Administered either as an IV infusion followed by a flush or using a syringe pump without a flush.

Timeline

• Start date: 2025-09-16
• Primary completion: 2028-03-18
• Completion: 2031-01-18
• First posted: 2025-06-25
• Last updated: 2026-03-27

Locations

19 sites across 3 countries: United States, South Korea, Turkey (Türkiye)

Regulatory

• FDA-regulated drug study